• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    3/16/22 8:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery

    Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT

    CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting, being held in Denver, March 16-19. Highlights are:  

    • LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection
    • LB1148 reduced extent and severity of adhesions by 93% in patients undergoing bowel resection
    • The incidence of adhesions in the placebo group was similar to the published incidence (89% and ≥90% respectively)
    • 100% of placebo-treated subjects underwent a laparoscopic procedure, and 8 of 9 had ≥ 1 adhesions
    • 75% of the 8 LB1148-treated subjects underwent a laparoscopic procedure, and 2 of 6 had ≥ 1 adhesions
      • 25% of the 8 LB1148-treated subjects underwent a laparotomy, and neither formed adhesions
    • No drug-related serious adverse events occurred in the trials

    "The pooled results from these studies suggest that LB1148 has the potential to prevent postoperative adhesions," said Michael Dawson, M.D., Chief Medical Officer of Palisade Bio. "There is significant unmet need to prevent and reduce adhesions, as they are found in more than 90% of cases after intraabdominal surgery and patients tend to suffer life-long complications. These data are promising as we focus on our mission of protecting intestinal integrity and improving treatment options for patients."

    Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery. Study LBS-IST-POI-101 was a Phase 1, single-center, open-label, study enrolling 11 subjects undergoing GI surgery. The PROFILE-CN study was a 120-subject Phase 2, randomized, double-blind, placebo-controlled study conducted in collaboration with co-development partner, Newsoara Biopharma to evaluate LB1148 for return of GI function in subjects undergoing planned bowel resection surgery. In both trials, a subset of subjects went on to have a second surgery (e.g., stoma take down). In these subjects, adhesions were assessed and quantified at the time of surgical closure during the initial surgery and at the time of opening at the subsequent surgical procedure.

    "We are excited about this data as they are extremely encouraging given adhesion prevalence in patients who have abdominal surgery and the serious complications that can occur such as small bowel obstruction, infertility, and chronic abdominal pain.  Further, the FDA has recognized the important unmet need for adhesions therapeutics and granted Fast Track designation to LB1148 for the reduction of post-surgical intraabdominal and pelvic adhesions," said Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio. "We believe LB1148 can help reduce adhesions and reduce adhesions related complications, while potentially driving down costs for the healthcare system. These studies provide critically important data as we continue to research the potential for LB1148 to reduce post-surgical intraabdominal adhesions in our phase 2 study."

    A total of 3/11 subjects in LBS-IST-POI-101 and 14/120 subjects in LBS-POI-201-CN underwent a second surgery. Data were pooled from the two trials and the incidence as well as the extent, and severity of adhesions were compared for subjects treated with LB1148 versus placebo.

    Conference Call

    Stonegate Capital Partners will host a conference call today, March 16, 2022, 5:30 a.m. Pacific Time/7:30 a.m. Central Time/8:30 a.m. Eastern Time to further discuss the data. You must register before the webcast to be able to access it. Please click the link below to register for the webcast: https://us06web.zoom.us/webinar/register/WN_ThNZHlT4Q9mBMGrMlxabkg

    About LB1148

    LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays.

    About Palisade Bio 

    Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset LB1148, advancing towards Phase 3, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return of bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.

    About Newsoara Biopharma

    Newsoara is a biotech company based in Shanghai, China with research laboratories in the Suzhou BioBAY focusing on novel drug research and development to address unmet medical needs in patients with various diseases.

    Forward Looking Statements

    This communication contains "forward-looking" statements, including, without limitation, statements related to expectations regarding Palisade's plans for future presentations at investor conferences. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade's current expectations. Forward-looking statements involve risks and uncertainties. Palisade's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company's ability to advance its clinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bio's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Palisade Bio Investor Relations Contact:

    Dawn Hofmeister

    [email protected]

    Palisade Bio Media Relations Contact:

    CORE IR

    Jules Abraham

    [email protected]

    917-885-7378



    Primary Logo

    Get the next $PALI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

      Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from

      5/6/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

      Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA. Details of the oral presentation are as follows: Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient OutcomesTitle: Improving

      5/1/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

      Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune,

      4/9/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    SEC Filings

    See more
    • Palisade Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      5/2/25 4:11:24 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Palisade Bio Inc.

      10-K - PALISADE BIO, INC. (0001357459) (Filer)

      3/24/25 4:20:12 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:30:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      11/14/24 3:35:13 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/24 2:54:03 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/13/24 8:10:04 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Financials

    Live finance-specific insights

    See more
    • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

      Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

      3/16/22 8:00:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Leadership Updates

    Live Leadership Updates

    See more
    • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

      Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

      12/17/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints Margery Fischbein to its Board of Directors

      Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

      5/7/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

      Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

      2/8/24 2:40:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:58:18 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO, CFO Finley John David

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:56:42 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wei Binxian converted options into 388 units of Comon Stock, increasing direct ownership by 83% to 855 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      11/22/24 4:00:10 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

      Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

      2/2/22 7:38:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group initiated coverage on Palisade Bio with a new price target

      Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

      8/31/21 8:02:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/29/24 3:47:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/28/24 6:02:01 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/7/24 8:30:10 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care